InvestorsHub Logo
Followers 840
Posts 120462
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Friday, 08/16/2019 3:04:21 PM

Friday, August 16, 2019 3:04:21 PM

Post# of 768
FDA approves ABBV’s Rinvoq (upadacitinib) for RA:

https://finance.yahoo.com/news/abbvie-receives-fda-approval-rinvoq-164300881.html

https://finance.yahoo.com/news/1-fda-approves-abbvies-rheumatoid-164927079.html

Rinvoq is an oral JAK inhibitor; it is one of the drugs ABBV is counting on to make up the slack as Humira sales decline from the uptake of biosimilars.

The US list price of Rinvoq is ~$59K per annum, which is slightly less than Humira.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News